FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Levy Howard 2. Issuer Name and Ticker or Trading Symbol CATALYST BIOSCIENCES, INC. [ CBIO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)         (First)         (Middle)
611 GATEWAY BOULEVARD, SUITE 710
3. Date of Earliest Transaction (MM/DD/YYYY)
2/8/2021
(Street)
SOUTH SAN FRANCISCO, CA 94080
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
2/10/2021 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $5.89  2/8/2021    A     25000       (1) 2/8/2031  Common Stock  25000  $0.00  25000  D   

Explanation of Responses:
(1)  Award vests and will become exercisable monthly over 48 months, with 25% of the shares vesting on the 12-month anniversary of the date hereof, and the remainder vesting monthly thereafter at the rate of 1/48th of the total number of shares.

Remarks:
The sole purpose of this amendment to the Form 4 filed on February 10, 2021, is to correct the vesting schedule.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Levy Howard
611 GATEWAY BOULEVARD, SUITE 710
SOUTH SAN FRANCISCO, CA 94080


Chief Medical Officer

Signatures
/s/ Faisal Shawwa Attorney-in-Fact for Howard Levy 4/26/2021
**Signature of Reporting Person Date
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Jul 2021 to Aug 2021 Click Here for more Catalyst Biosciences Charts.
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2020 to Aug 2021 Click Here for more Catalyst Biosciences Charts.